A detailed history of Anderson Hoagland & CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Anderson Hoagland & CO holds 21,262 shares of VRTX stock, worth $8.68 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares
21,262
Previous 21,236 0.12%
Holding current value
$8.68 Million
Previous $9.95 Million 0.65%
% of portfolio
1.03%
Previous 1.08%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$460.0 - $505.78 $11,960 - $13,150
26 Added 0.12%
21,262 $9.89 Million
Q2 2024

Jul 10, 2024

BUY
$392.81 - $485.53 $24,747 - $30,588
63 Added 0.3%
21,236 $9.95 Million
Q1 2024

Apr 11, 2024

BUY
$407.69 - $446.08 $1.83 Million - $2.01 Million
4,499 Added 26.98%
21,173 $8.85 Million
Q4 2023

Jan 17, 2024

BUY
$343.0 - $410.68 $5.72 Million - $6.85 Million
16,674 New
16,674 $6.78 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Anderson Hoagland & CO Portfolio

Follow Anderson Hoagland & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anderson Hoagland & CO, based on Form 13F filings with the SEC.

News

Stay updated on Anderson Hoagland & CO with notifications on news.